NEW YORK (GenomeWeb) – System Biosciences said today that Qiagen has signed a non-exclusive, worldwide license for SBI's ExoQuick exosome isolation technology for research use.
Qiagen intends to use the technology in its precipitation-based miRcury Exosome Kits, complementing its spin column-based exoEasy and exoRNeasy products.
"Qiagen's license demonstrates the value of ExoQuick technology for high-throughput, scalable isolation of exosomes from a range of biofluid samples," Jake Lesnik, vice president of commercial development at SBI, said in a statement. "The license agreement also demonstrates SBI's commitment to protecting its proprietary ExoQuick technology, which is used by thousands of researchers globally for fast and efficient exosome isolation."
Besides ExoQuick, Palo Alto, California-based SBI provides several exosome research tools and services including ExoFBS, ExoFlow, Exo-fect, and ExoGlow technologies, as well as Exo-NGS and ExoMS services for exosomal RNA-seq and proteomics analysis, respectively.